Observational study results in glaucoma patients undergoing a regimen replacement to fixed combination travoprost 0.004%/timolol 0.5% in Germany

Journal of Ocular Pharmacology and Therapeutics

Volumn 24, Issue 4, 2008, Pages 414-420

  Arend, Kay Oliver ^a   Raber, Thomas ^b  

^a Augenzentrum Alsdorf ^*  (Germany)

^b Alcon Pharma GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BIMATOPROST; BIMATOPROST PLUS TIMOLOL; DORZOLAMIDE PLUS TIMOLOL; LATANOPROST; PROSTAGLANDIN DERIVATIVE; TIMOLOL; TIMOLOL PLUS TRAVOPROST; TRAVOPROST;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; GERMANY; GLAUCOMA; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; OBSERVATIONAL STUDY; OPEN STUDY; STATISTICAL ANALYSIS;

AGED; CHEMISTRY, PHARMACEUTICAL; CLOPROSTENOL; DRUG COMBINATIONS; FEMALE; GERMANY; GLAUCOMA; HUMANS; MALE; MIDDLE AGED; TIMOLOL;

EID: 48949088345     PISSN: 10807683     EISSN: None     Source Type: Journal    
DOI: 10.1089/jop.2007.0123     Document Type: Article

References (45)

1. Maier, P.C., Funk, J., Schwarzer, G., et al. Treatment of ocular hypertension and open angle glaucoma: Meta-analysis of randomised controlled trials. BMJ 331:134-136B, 2005.
2. Bengtsson, B., and Heijl, A. A long-term prospective study of risk factors for glaucomatous visual field loss in patients with ocular hypertension. J. Glaucoma 14:135-138, 2005.
3. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. The AGIS Investigators. Am. J. Ophthalmol. 130:429-440, 2000.
4. Dailey, R.A., Brubaker, R.F., and Bourne, W.M. The effects of timolol maleate and acetazolamide on the rate of aqueous formation in normal human subjects. Am. J. Ophthalmol. 93:232-237, 1982.
5. Schachtschabel, U., Lindsey, J.D., and Weinreb, R.N. The mechanism of action of prostaglandins on uveoscleral outflow. Curr. Opin. Ophthalmol. 11:112-115, 2000.
6. Alm, A. Prostaglandin derivates as ocular hypotensive agents. Prog. Retin. Eye Res. 17:291-312, 1998.
7. Camras, C.B. Mechanism of the prostaglandin-induced reduction of intraocular pressure in humans. Adv. Prostagland. Thrombox. Leukot. Res. 23:519-525, 1995.
8. Ferrer, E. Trabecular meshwork as a new target for the treatment of glaucoma. Drug News Perspect. 19:151-158, 2006.
9. Brubaker, R.F. Targeting outflow facility in glaucoma management. Surv. Ophthalmol. 48:(Suppl. 1), S17-S20, 2003.
10. Kass, M.A., Heuer, D.K., Higginbotham, E.J., et al. The Ocular Hypertension Treatment Study: A randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch. Ophthalmol. 120:701-713; discussion, 829-830, 2002.
11. Heijl, A., Leske, M.C., Bengtsson, B., et al. The Early Manifest Glaucoma Trial Group. Reduction of intraocular pressure and glaucoma progression: Results from the Early Manifest Glaucoma Trial. Arch. Ophthalmol. 120:1268-1279, 2002.
12. Forsman, E., Kivela, T., and Vesti, E. Lifetime visual disability in open-angle glaucoma and ocular hypertension. J. Glaucoma. 16:313-319, 2007.
13. Nouri-Mahdavi, K., Hoffman, D., Coleman, A.L., et al. The Advanced Glaucoma Intervention Study. Predictive factors for glaucomatous visual field progression in the Advanced Glaucoma Intervention Study. Ophthalmology 111:1627-1635, 2004.
14. Asrani, S., Zeimer, R., Wilensky, J., et al. Large diurnal fluctuations in intraocular pressure are an independent risk factor in patients with glaucoma. J. Glaucoma 9:134-142, 2000.
15. Zeimer, R.C., Wilensky, J.T., Gieser, D.K., et al. Association between intraocular pressure peaks and progression of visual field loss. Ophthalmology 98:64-69, 1991.
16. Higginbotham, E.J., Feldman, R., Stiles, M., et al. The Fixed Combination Investigative Group. Latanoprost and timolol combination therapy versus monotherapy: One-year randomized trial. Arch. Ophthalmol. 120:915-922, 2002.
17. Denis, P., Andrew, R., Wells, D., et al. A comparison of morning and evening instillation of a combination travoprost 0.004%/timolol 0.5% ophthalmic solution. Eur. J. Ophthalmol. 16:407-415, 2006.
18. Hughes, B.A., Bacharach, J., Craven, E.R., et al. A three-month, multicenter, double-masked study of the safety and efficacy of travoprost 0.004%/timolol 0.5% ophthalmic solution compared to travoprost 0.004% ophthalmic solution and timolol 0.5% dosed concomitantly in subjects with open-angle glaucoma or ocular hypertension. J. Glaucoma 14:392-399, 2005.
19. Schuman, J.S., Katz, G.J., Lewis, R.A., et al. Efficacy and safety of a fixed combination of travoprost 0.004%/timolol 0.5% ophthalmic solution once-daily for open-angle glaucoma or ocular hypertension. Am. J. Ophthalmol. 140:242-250, 2005.
20. Franks, W.A., Renard, J.P., Cunliffe, I.A., et al. A 6-week, double-masked, parallel-group study of the efficacy and safety of travoprost 0.004% compared with latanoprost 0:005%/timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension. Clin. Ther. 28:332-339, 2006.
21. Hommer, A., for the Ganfort Investigators Group. I. A double-masked, randomized, parallel comparison of a fixed combination of bimatoprost 0.03%/timolol 0.5% with nonfixed combination use in patients with glaucoma or ocular hypertension. Eur. J. Ophthalmol. 17:53-62, 2007.
22. Mitchell, C.H., Fleischhauer, J.C., Stamer, W.D., et al. Human trabecular meshwork cell volume regulation. Am. J. Physiol. Cell Physiol. 283:C315-C326, 2002.
23. Wordinger, R.J., Fleenor, D.L., Hellberg, P.E., et al. Effects of TGF-beta2, BMP-4, and gremlin in the trabecular mesh-work: Implications for glaucoma. Invest. Ophthalmol. Vis. Sci. 48:1191-1200, 2007.
24. Thieme, H., Schimmat, C., Munzer, G., et al. Endothelin antagonism: Effects of FP receptor agonists prostaglandin F2 alpha and fluprostenol on trabecular meshwork contractility. Invest. Ophthalmol. Vis. Sci. 47:938-945, 2006.
25. Nilsson, S.F. The uveoscleral outflow routes. Eye 11(Pt. 2):149-154, 1997.
26. Crawford, K., and Kaufman, P.L. Pilocarpine antagonizes prostaglandin F2-alpha-induced ocular hypotension in monkeys. Evidence for enhancement of uveoscleral outflow by prostaglandin F2 alpha. Arch. Ophthalmol. 105:1112-1116, 1987.
27. Nilsson, S.F., Samuelsson, M., Bill, A., et al. Increased uveoscleral outflow as a possible mechanism of ocular hypotension caused by prostaglandin F2 alpha-1-isopropylester in the cynomolgus monkey. Exp. Eye Res. 48:707-716, 1989.
28. Gabelt, B.T., and Kaufman, P.L. The effect of prostaglandin F2 alpha on trabecular outflow facility in cynomolgus monkeys. Exp. Eye Res. 51:87-91, 1990.
29. Weinreb, R.N., Toris, C.B., Gabelt, B.T., et al. Effects of prostaglandins on the aqueous humor outflow pathways. Surv. Ophthalmol. 47(Suppl. 1):S53-S64, 2002.
30. Toris, C.B., Zhan, G.L., Camras, C.B., et al. Effects of travoprost on aqueous humor dynamics in monkeys. J. Glaucoma 14:70-73, 2005.
31. Dinslage, S., Hueber, A., Diestelhorst, M., et al. The influence of latanoprost 0.005% on aqueous humor flow and outflow facility in glaucoma patients: A double-masked, placebo-controlled clinical study. Graefe's Arch. Clin. Exp. Ophthalmol. 242:654-660, 2004.
32. Ziai, N., Dolan, J.W., Kacere, R.D., et al. The effects on aqueous dynamics of PhXA41, a new prostaglandin F2 alpha analogue, after topical application in normal and ocular hypertensive human eyes. Arch. Ophthalmol. 111: 1351-1358, 1993.
33. Gabelt, B.T., and Kaufman, P.L. Prostaglandin F2 alpha increases uveoscleral outflow in the cynomolgus monkey. Exp. Eye Res. 49:389-402, 1989.
34. Kiland, J.A., Gabelt, B.T., and Kaufman, P.L. Studies on the mechanism of action of timolol and on the effects of suppression and redirection of aqueous flow on outflow facility. Exp. Eye Res. 78:639-651, 2004.
35. Toris, C.B., Zhan, G., and Camras, C.B. Increase in outflow facility with unoprostone treatment in ocular hypertensive patients. Arch. Ophthalmol. 122:1782-1787, 2004.
36. Toris, C.B., Zhan, G., Fan, S., et al. Effects of travoprost on aqueous humor dynamics in patients with elevated intraocular pressure. J. Glaucoma 16:189-195, 2007.
37. Bahler, C.K., Howell, K.G., Hann, C.R., et al. Prostaglandins increase trabecular meshwork outflow facility in cultured human anterior segments. Am. J. Ophthalmol. 145:114-119, 2008. [Epub 2007 Nov 7]
38. Crowston, J.G., and Weinreb, R.N. Glaucoma medication and aqueous humor dynamics. Curr. Opin. Ophthalmol. 16:94-100, 2005.
39. Zimmerman, T.J., and Stewart, W.C., for the Latanoprost Axis Study Group. Intraocular pressure, safety, and quality of life in glaucoma patients switching to latanoprost from monotherapy treatments. J. Ocul. Pharmacol. Ther. 19: 405-415, 2003.
40. Stewart, W.C., Holmes, K.T., and Johnson, M.A. Washout periods for brimonidine 0.2% and latanoprost 0.005%. Am. J. Ophthalmol. 131:798-799, 2001.
41. Barnebey, H.S., Orengo-Nania, S., Flowers, B.E., et al. The safety and efficacy of travoprost 0.004%/timolol 0.5% fixed-combination ophthalmic solution. Am. J. Ophthalmol. 140:1-7, 2005.
42. Hellberg, M.R., Sallee, V.L., McLaughlin, M.A., et al. Preclinical efficacy of travoprost, a potent and selective FP prostaglandin receptor agonist. J. Ocul. Pharmacol. Ther. 17:421-432, 2001.
43. Sit, A.J., Weinreb, R.N., Crowston, J.G., et al. Sustained effect of travoprost on diurnal and nocturnal intraocular pressure. Am. J. Ophthalmol. 141:1131-1133, 2006.
44. Dubiner, H.B., Sircy, M.D., Landry, T., et al. Comparison of the diurnal ocular hypotensive efficacy of travoprost and latanoprost over a 44-h period in patients with elevated intraocular pressure. Clin. Ther. 26:84-91, 2004.
45. Yalon, M., Urinowsky, E., Rothkoff, L., et al. Frequency of timolol administration. Am. J. Ophthalmol. 92:526-529, 1981.